1019021-93-2

Basic information

• Product Name: 7-bromoimidazo[1,2-a]pyridine-3-carboxylic acid
• Synonyms: 7-bromoimidazo[1,2-a]pyridine-3-carboxylic acid;CHEMMAKER CMFS-00751;IMidazo[1,2-a]pyridine-3-carboxylic acid, 7-broMo-;EOS-60894
• CAS NO: 1019021-93-2
• Molecular Formula: C8H5BrN2O2
• Molecular Weight: 241.0415
• Mol File: 1019021-93-2.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Density: 1.89±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.02±0.41(Predicted)
• CAS DataBase Reference: 7-bromoimidazo[1,2-a]pyridine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 7-bromoimidazo[1,2-a]pyridine-3-carboxylic acid(1019021-93-2)
• EPA Substance Registry System: 7-bromoimidazo[1,2-a]pyridine-3-carboxylic acid(1019021-93-2)

Safety Data

• Hazardous Substances Data: 1019021-93-2(Hazardous Substances Data)

Usage

General Description

7-bromoimidazo[1,2-a]pyridine-3-carboxylic acid is a chemical compound with the molecular formula C8H5BrN3O2. It is a heterocyclic compound that contains a pyridine ring with an imidazole ring fused to it. The presence of a carboxylic acid group at the 3-position makes it a carboxylic acid derivative. 7-bromoimidazo[1,2-a]pyridine-3-carboxylic acid is often used as a building block in the synthesis of pharmaceuticals and agrochemicals. Its unique structure and properties make it a valuable intermediate in the development of new drugs and crop protection products. Additionally, it has been studied for its potential biological activities and therapeutic applications.

Upstream product

• 1134327-98-2 7-bromoimidazo[1,2-a]pyridin-3-carboxylate ethyl ester 
• 84249-14-9 2-amino-4-bromopyridine 

Downstream Products

• 1426135-85-4 methyl 3-(3-(3-(7-bromoimidazo[1,2-a]pyridine-3-carboxamido)-4-methylphenyl)-1,2,4-oxadiazol-5-yl)azetidine-1-carboxylate 
• 1426531-90-9 3-(5-carboxy-2-fluorophenylcarbamoyl)-7-(1-methyl-1H-pyrazol-5-yl)imidazo[1,2-a]pyridin-1-ium chloride 
• 1426530-70-2 3-[(7-bromo-imidazo[1,2-a]pyridine-3-carbonyl)-amino]-4-fluoro-benzoic acid methyl ester 
• 1426531-24-9 4-fluoro-3-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamido)benzoic acid 
• 1426530-75-7 N-(2-fluoro-5-((2-(4-methylpiperazin-1-yl)benzyl)carbamoyl)phenyl)-7-(pyridin-3-yl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426530-74-6 7-(1-methyl-1H-pyrazol-5-yl)-N-(2-methyl-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426530-72-4 7-bromo-N-(2-methyl-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426530-94-0 4-fluoro-3-{[7-(2-methyl-2H-pyrazol-3-yl)-imidazo[1,2-a]pyridine-3-carbonyl]-amino}-benzoic acid 
• 1426530-71-3 7-(3-fluoro-4-(2-hydroxyethylcarbamoyl)phenyl)-N-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426530-69-9 7-bromo-N-(2-fluoro-5-(2-(4-methylpiperazin-1-yl)benzylcarbamoyl)phenyl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426530-82-6 N-(5-((2-(2,6-cis-dimethylpiperidin-1-yl)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1H-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426530-77-9 N-(2-fluoro-5-((2-(4-methylpiperazin-1-yl)benzyl)carbamoyl)phenyl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426530-68-8 N-(2-fluoro-5-((2-(4-methylpiperazin-1-yl)benzyl)carbamoyl)phenyl)-7-(1-methyl-1H-pyrazol-5-yl)imidazo[1,2-a]pyridine-3-carboxamide 
• 1426531-23-8 N-(5-((2-(2,2-dimethylpyrrolidin-1-yl)ethyl)carbamoyl)-2-fluorophenyl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide 

Relevant articles and documents

SOLID FORMS OF BICYCLIC HETEROCYCLIC DERIVATIVES AS PDGF RECEPTOR MEDIATORS

The present invention provides novel solid forms of pharmaceutically active agents and therapeutic uses thereof. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase